BiotechTube

enzastaurin + placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Hodgkin Lymphoma

Conditions

Non Hodgkin Lymphoma

Trial Timeline

Jun 1, 2006 → Jul 1, 2013

NCT ID
NCT00332202

About enzastaurin + placebo

enzastaurin + placebo is a phase 3 stage product being developed by Eli Lilly for Non Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00332202. Target conditions include Non Hodgkin Lymphoma.

What happened to similar drugs?

9 of 20 similar drugs in Non Hodgkin Lymphoma were approved

Approved (9) Terminated (2) Active (9)
✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved
✅rituximab [MabThera/Rituxan]RocheApproved
✅TenofovirGilead SciencesApproved
✅temsirolimus + temsirolimusPfizerApproved
✅Kepivance (Palifermin)Swedish Orphan BiovitrumApproved
✅Entecavir prophylaxis + Therapeutic entecavirBristol Myers SquibbApproved
✅Granulocyte-colony stimulating factor (G-CSF) + Fixed Dose Plerixafor + Weight-Based PlerixaforSanofiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00414960Phase 2Completed
NCT00415363Phase 2Completed
NCT00332202Phase 3Completed

Competing Products

20 competing products in Non Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
AFM13AffimedPhase 2
25
VIP152 + BTKiVincerx PharmaPhase 1
11
PLX3397Daiichi SankyoPhase 2
35
YM155 + RituximabAstellas PharmaPhase 2
35
TazemetostatEisaiPhase 2
35
ONTAKEisaiPhase 2
35
TazemetostatEisaiPhase 1
29
ME-401Kyowa KirinPhase 1
29
ME-401Kyowa KirinPhase 2
39
TirabrutinibOno PharmaceuticalPhase 1
29
ONO-7018Ono PharmaceuticalPhase 1
33
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
32
ONO-7018 + ONO-7018Ono PharmaceuticalPhase 1
33
R-mabHDI and ABVD + ABVDEli LillyPhase 3
36
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
32
gemcitabineEli LillyPhase 2
27
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
35
LY4152199 - IVEli LillyPhase 1
36
R-mabHD + ABVDEli LillyPhase 2
31
LY317615Eli LillyPhase 2
35